ES2104733T3 - Derivados de indol. - Google Patents

Derivados de indol.

Info

Publication number
ES2104733T3
ES2104733T3 ES91920239T ES91920239T ES2104733T3 ES 2104733 T3 ES2104733 T3 ES 2104733T3 ES 91920239 T ES91920239 T ES 91920239T ES 91920239 T ES91920239 T ES 91920239T ES 2104733 T3 ES2104733 T3 ES 2104733T3
Authority
ES
Spain
Prior art keywords
alkyl
hydrogen
aryl
migraa
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91920239T
Other languages
English (en)
Inventor
John Eugene Macor
Martin James Wythes
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PFIZER
Pfizer Inc
Original Assignee
PFIZER
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24393510&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2104733(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by PFIZER, Pfizer Inc filed Critical PFIZER
Application granted granted Critical
Publication of ES2104733T3 publication Critical patent/ES2104733T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Addiction (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Electroluminescent Light Sources (AREA)
  • Lasers (AREA)

Abstract

COMPUESTOS DE FORMULA (I), EN DONDE N ES 0, 1 O 2; R1 ES HIDROGENO; R2 SE SELECCIONA DE HIDROGENO, HALOGENO, CIANO, OR4, -(CH2)M (C=O)NR5R6, -(CH2)M -(CH2)M NR7SO2R8, -(CH2)M -(CH2)M NR7(C=O)OR9, Y -CH=CH(CH2)YR10; R3 SE SELECCIONA DE HIDROGENO Y ALQUILO C1 A C6 LINEAL O RAMIFICADO; R4 SE SELECCIONA DE HIDROGENO, ALQUILO C1 A C6, O ARILO; R5 Y R6 SE SELECCIONAN INDEPENDIENTEMENTE DE HIDROGENO, ALQUILO C1 A C6, ARILO, O ALQUILO ANILLO DE 4, 5 O 6 MIEMBROS; R7 Y R8 SE SELECCIONAN INDEPENDIENTEMENTE DE HIDROGENO, ALQUILO C1 A C6, ARILO, Y ALQUILO LO C1 A C3; R9 SE SELECCIONA DE HIDROGENO, ALQUILO C1 A C6, ARILO, O ALQUILO R6 Y -SO2NR5R6, EN DONDE R5 Y R6 SE DEFINEN COMO ANTERIORMENTE, Y -NR7(C=O)R8, -NR7SO2R8, -NR7(C=O)NR5R6, -S(O)XR8 Y -NR7(C=O)OR9, EN DONDE R7, R8, Y R9 SON COMO SE DEFINIERON ANTERIORMENTE; Y ES 0, 1 O 2; X ES 1 O 2; M ES 0, 1, 2, O 3; Y LOS GRUPOS ARILO ANTERIORES Y LAS MITADES ARILO DE LOS ANTERIORES GRUPOS ALQUILO - ARILO SE SELECCIONAN INDEPENDIENTEMENTE ENTRE FENILO O FENILO SUSTITUIDO, EN DONDE DICHO FENILO SUSTITUIDO PUEDE ESTAR SUSTITUIDO CON UNO O TRES GRUPOS ESCOGIDOS DE ALQUILO C1 A C4, HALOGENO, HIDROXILO, CIANO, CARBOXIAMIDO, NITRO, Y ALCOXILO C1 A C4 Y LAS SALES DE ELLOS FARMACEUTICAMENTE ACEPTABLES SON NUEVOS. ESTOS COMPUESTOS SE USAN COMO PSICOTERAPEUTICOS Y SON POTENTES AGONISTAS DE SEROTONINA (5-HT1) Y SE PUEDEN USAR EN EL TRATAMIENTO DE DEPRESION, ANSIEDAD, DESORDENES ALIMENTICIOS, OBESIDAD, ABUSO DE DROGAS, CEFALEA EN RACIMOS, MIGRAÑA, DOLOR, HEMICRANIA PAROXISMICA CRONICA Y CEFALEA ASOCIADA CON DESORDENES VASCULARES, Y OTROS DESORDENES QUE SURGEN A PARTIR DE DEFICIENTE NEUROTRANSMISION SEROTONERGICA. LOS COMPUESTOS PUEDEN TAMBIEN SER USADOS COMO ANTIHIPERTENSIVOS QUE ACTUAN CENTRALMENTE Y VASODILATADORES.
ES91920239T 1990-10-15 1991-10-08 Derivados de indol. Expired - Lifetime ES2104733T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US59792890A 1990-10-15 1990-10-15

Publications (1)

Publication Number Publication Date
ES2104733T3 true ES2104733T3 (es) 1997-10-16

Family

ID=24393510

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91920239T Expired - Lifetime ES2104733T3 (es) 1990-10-15 1991-10-08 Derivados de indol.

Country Status (33)

Country Link
EP (1) EP0592438B1 (es)
JP (2) JP2575272B2 (es)
KR (1) KR0179053B1 (es)
CN (1) CN1039322C (es)
AT (1) ATE157361T1 (es)
AU (1) AU651637B2 (es)
BG (1) BG61975B1 (es)
BR (2) BR9106978A (es)
CA (1) CA2091562C (es)
DE (3) DE69127468T2 (es)
DK (1) DK0592438T5 (es)
EG (1) EG20224A (es)
ES (1) ES2104733T3 (es)
FI (1) FI105812B (es)
GR (1) GR3025087T3 (es)
HU (2) HUT64326A (es)
IE (1) IE913555A1 (es)
IL (3) IL99701A (es)
LU (1) LU90902I2 (es)
MX (1) MX9101606A (es)
MY (1) MY111683A (es)
NL (1) NL300070I2 (es)
NO (3) NO305121B1 (es)
NZ (2) NZ240217A (es)
OA (1) OA09874A (es)
PL (3) PL170330B1 (es)
PT (1) PT99218B (es)
RO (1) RO111767B1 (es)
RU (1) RU2095360C1 (es)
SG (1) SG54270A1 (es)
WO (1) WO1992006973A1 (es)
YU (1) YU48088B (es)
ZA (1) ZA918156B (es)

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5545644A (en) * 1990-10-15 1996-08-13 Pfizer Inc. Indole derivatives
US5559246A (en) * 1990-10-15 1996-09-24 Pfizer Inc. Indole derivatives
US5559129A (en) * 1990-10-15 1996-09-24 Pfizer Inc Indole derivatives
US5607951A (en) * 1990-10-15 1997-03-04 Pfizer Inc Indole derivatives
US5578612A (en) * 1990-10-15 1996-11-26 Pfizer Inc. Indole derivatives
DE69230803T2 (de) * 1991-11-25 2000-12-07 Pfizer Inc., New York 5-(hetero- oder carbocyclylamino)-indol derivate, deren herstellung und deren verwendung als 5-ht1 agonisten
TW288010B (es) * 1992-03-05 1996-10-11 Pfizer
PL172405B1 (en) * 1992-04-07 1997-09-30 Pfizer Derivatives of indole
GB9207930D0 (en) * 1992-04-10 1992-05-27 Pfizer Ltd Indoles
UA34452C2 (uk) * 1992-04-10 2001-03-15 Пфайзер Інк. Похідні ациламіноіндолу, що проявляють серотонінову 5-нт1 агоністичну активність та похідні аміноіндолу як проміжні сполуки
GB9208161D0 (en) * 1992-04-14 1992-05-27 Pfizer Ltd Indoles
GB9210400D0 (en) * 1992-05-15 1992-07-01 Merck Sharp & Dohme Therapeutic agents
GB9211277D0 (en) 1992-05-28 1992-07-15 Glaxo Group Inc Pharmaceutical compositions
TW251284B (es) * 1992-11-02 1995-07-11 Pfizer
FR2701026B1 (fr) * 1993-02-02 1995-03-31 Adir Nouveaux dérivés de l'indole, de l'indazole et du benzisoxazole, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent.
IT1271352B (it) * 1993-04-08 1997-05-27 Boehringer Ingelheim Italia Derivati dell'indolo utili nel trattamento dei disturbi del sistema nervoso centrale
AU6567094A (en) * 1993-04-22 1994-11-08 Pfizer Research And Development Company, N.V./S.A. Indole derivatives as 5-h1-like agonists for use in migraine
AP486A (en) * 1993-04-27 1996-04-16 Pfizer Indole derivatives.
ES2070772B1 (es) * 1993-08-09 1996-02-16 Pfizer Derivados de acilaminoindol
CA2169179C (en) * 1993-08-31 2000-02-29 John E. Macor 5-arylindole derivatives
AU3162695A (en) * 1994-08-03 1996-03-04 Asta Medica Aktiengesellschaft Indol, indazol, pyridopyrrol and pyridopyrazol derivatives with anti-asthmatic, anti-allergic, anti-inflammatory and immunomodulating effects
GB9417310D0 (en) * 1994-08-27 1994-10-19 Pfizer Ltd Therapeutic agents
ATE224388T1 (de) * 1994-10-12 2002-10-15 Pfizer Res & Dev Indolderivate zur behandlung von migräne
AU726560B2 (en) * 1994-10-12 2000-11-09 Pfizer Research And Development Company, N.V./S.A. Use of indole derivatives for the treatment of various diseases
GB9420529D0 (en) 1994-10-12 1994-11-30 Pfizer Ltd Indoles
GB9424471D0 (en) * 1994-12-03 1995-01-18 Pfizer Ltd Treatment of emesis
AU702322B2 (en) * 1995-03-20 1999-02-18 Eli Lilly And Company 5-substituted-3-(1,2,3,6-tetrahydropyridin-4-yl)- and 3-(piperidin-4-yl)-1h-indoles: new 5-ht1f agonists
GB9510223D0 (en) * 1995-05-20 1995-07-19 Pfizer Ltd Therapeutic agent
US5945118A (en) * 1995-09-29 1999-08-31 Pfizer Inc Indole derivative for the treatment of migraine
GB9714383D0 (en) * 1997-07-08 1997-09-10 Pfizer Ltd Improved process
US7189753B1 (en) 1997-11-06 2007-03-13 Cady Roger K Preemptive prophylaxis of migraine
AU3170099A (en) * 1998-04-16 1999-11-08 Yamanouchi Pharmaceutical Co., Ltd. Remedies for obesity
GB9816556D0 (en) * 1998-07-30 1998-09-30 Pfizer Ltd Therapy
US5994352A (en) * 1998-11-13 1999-11-30 Pfizer Inc. 5-arylindole derivatives
GB9825988D0 (en) 1998-11-27 1999-01-20 Pfizer Ltd Indole derivatives
DE19858340A1 (de) * 1998-12-17 2000-06-21 Merck Patent Gmbh Verfahren zur Herstellung von 3-Alkanoyl- und 3-Alkylindolen
GB9922963D0 (en) * 1999-09-28 1999-12-01 Pfizer Ltd Polymorphic salt
JP2000336074A (ja) 1999-03-24 2000-12-05 Sumitomo Chem Co Ltd ［２−（アリールスルホニル）エテニル］ベンゼン誘導体の製造方法
GB9915231D0 (en) 1999-06-29 1999-09-01 Pfizer Ltd Pharmaceutical complex
CN1382123A (zh) * 1999-08-26 2002-11-27 藤泽药品工业株式会社 吲哚衍生物或其盐的制造方法
GB9923314D0 (en) * 1999-10-01 1999-12-08 Pfizer Ltd Acylation process
FR2799463B1 (fr) * 1999-10-12 2004-04-16 Adir Nouveaux composes cyano-indoles inhibiteurs de recapture de serotonine, leur procede de preparation et ces compositions pharmaceutiques qui les contiennent
RU2269523C2 (ru) * 2000-04-28 2006-02-10 Акадиа Фармасьютикалз, Инк. Мускариновые агонисты
GB0031094D0 (en) * 2000-12-20 2001-01-31 Pfizer Ltd New Process
US20030166704A1 (en) 2000-12-20 2003-09-04 Pfizer Inc. New process
US8329734B2 (en) 2009-07-27 2012-12-11 Afgin Pharma Llc Topical therapy for migraine
DK3168218T3 (en) 2001-08-15 2019-01-14 Pharmacia & Upjohn Co Llc Crystalline comprising an L-malic acid salt of N- [2- (DIETHYLAMINO) ETHYL] -5 - [(5-FLUOR-1,2-DIHYDRO-2-OXO-3H-INDOL-3-YLIDE) METHYL] -2,4 -DIMETHYL-1H-PYRROL-3-CARBOXAMIDE FOR USE AS A MEDICINE
US7132549B2 (en) 2003-05-30 2006-11-07 Pfizer Inc. Process
GB0312478D0 (en) * 2003-05-30 2003-07-09 Pfizer Ltd Improved process
US20070065463A1 (en) 2003-06-20 2007-03-22 Ronald Aung-Din Topical therapy for the treatment of migranes, muscle sprains, muscle spasms, spasticity and related conditions
USD571213S1 (en) 2005-05-12 2008-06-17 Pepsico, Inc. Portion of a bottle
ES2338699T3 (es) 2005-06-15 2010-05-11 Pfizer Limited Arilpirazoles sustituidos para uso contra parasitos.
US7645786B2 (en) 2005-06-15 2010-01-12 Pfizer Inc. Substituted arylpyrazoles
WO2006079999A2 (en) * 2006-04-09 2006-08-03 Barth Frederik H Induction of a novel state of mind with a 5-ht2a agonist and a nmda antagonist
US20090299077A1 (en) * 2008-05-22 2009-12-03 Vinod Kumar Kansal Salts of (R)-5-(2phenylsulphonylethenyl)-3-(N-methylpyrrolidin-2-ylmethyl)-1H-indole, 5-bromo-3-[(R)-1-methyl-pyrrolidin-2-ylmethyl]-1H-indole and of eletriptan
JP2011526889A (ja) 2008-06-30 2011-10-20 アフギン ファーマ，エルエルシー 局所局部的神経作用療法
EP2149573A1 (en) * 2008-08-01 2010-02-03 Laboratorios Del. Dr. Esteve, S.A. Substituted indole sulfonamide compounds their preparation and use as medicaments
IT1393700B1 (it) * 2009-04-22 2012-05-08 F S I Fabbrica Italiana Sint Sintesi di 3-{[(2r)-1-metilpirrolidin-2-il]metil}-5-[2-(fenilsulfonil)etil]-1h-indolo
WO2011004391A2 (en) 2009-06-25 2011-01-13 Matrix Laboratories Ltd An improved process for the preparation of eletriptan and its salt thereof
WO2011024039A1 (en) * 2009-08-25 2011-03-03 Ramesh Babu Potluri Synthesis of novel 5-(2-(phenylsulfonyl)ethyl)-1h-indole derivatives
US8754239B2 (en) 2010-01-19 2014-06-17 Sms Pharmaceuticals Limited Process for preparing eletriptan hydrobromide having α-form
CN102606426B (zh) * 2012-03-02 2014-05-21 王仲彦 踏步健身发电装置
WO2014063752A1 (en) 2012-10-26 2014-05-01 Synthon Bv Process for making crystalline form alpha of eletriptan hydrobromide
WO2014078568A1 (en) 2012-11-14 2014-05-22 The Johns Hopkins University Methods and compositions for treating schizophrenia
CN103408535B (zh) * 2013-08-13 2016-03-02 张家港威胜生物医药有限公司 一种依来曲普坦中间体-5-溴-3-(n-甲基吡咯啉-2-基甲基)-1h-吲哚合成工艺
US10383816B2 (en) 2015-03-02 2019-08-20 Afgin Pharma, Llc Topical regional neuro-affective therapy with cannabinoid combination products
HK1244715A1 (zh) 2015-03-02 2018-08-17 阿福金制药有限责任公司 用大麻素的局部区域神经影响性疗法
WO2017125351A1 (en) 2016-01-21 2017-07-27 Laboratorios Lesvi Sl Process for preparing (( r)-3-[(-1-methylpyrrolidin-2-yl)methyl]-5-(2-phenylsulfonylethyl)-1h-indole
CN106065008B (zh) * 2016-06-16 2018-06-05 黑龙江中医药大学 一种具有改善睡眠作用的吲哚-2-酰胺类化合物及其应用
US20180049994A1 (en) 2016-08-16 2018-02-22 Afgin Pharma, Llc Topical regional neuro-affective therapy with caryophyllene
TR201616365A1 (tr) 2016-11-14 2018-05-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Deksketoprofen ve eletri̇ptanin oral farmasöti̇k kompozi̇syonlari
TR201619983A2 (tr) 2016-12-29 2018-07-23 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Di̇klofenak ve eletri̇ptanin farmasöti̇k formülasyonlari
KR102129947B1 (ko) 2018-06-08 2020-07-03 김종창 콘크리트 타설을 위한 입체형 와이어 메쉬
EP3766483A1 (en) 2019-07-19 2021-01-20 BioPharma Synergies, S. L. Orodispersible powder composition comprising a triptan
JP7704364B2 (ja) 2020-01-22 2025-07-08 テクノファージ， インベスティガサン エ デセンボルビメント エム ビオテクノロジア，エスエー 脊髄損傷の治療及び移動運動機能の改善のためのエレトリプタン臭化水素酸塩
KR20230154219A (ko) * 2021-03-02 2023-11-07 마인드셋 파마 인크. 세로토닌성 작용제와 관련된 장애의 치료에 유용한 세로토닌성 작용제로서의 인돌 유도체
CA3243296A1 (en) * 2022-02-01 2023-08-10 Caamtech, Inc. PSYCHEDELIC COMPOUNDS AND THEIR THERAPEUTIC USES
WO2025104491A1 (en) 2023-11-14 2025-05-22 Mindset Pharma Inc. Indole derivatives as serotonergic agents useful for the treatment of disorders related thereto
CN121362179A (zh) * 2024-07-19 2026-01-20 纽欧申医药(上海)有限公司 含吡咯环化合物、其药物组合物及其应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL74527C (es) *
US2773875A (en) * 1952-03-28 1956-12-11 Hoffmann La Roche Indole derivatives and method for producing same
GB886684A (en) * 1957-09-17 1962-01-10 Upjohn Co Improvements in or relating to heterocyclic compounds and the manufacture thereof
GB851780A (en) * 1958-02-25 1960-10-19 Rhone Poulenc Sa New indole derivatives
US3037031A (en) * 1959-08-04 1962-05-29 Warner Lambert Pharmaceutical Derivatives of 3-(2-aminoalkyl)-5-indolol and process therefor
GB893707A (en) * 1960-03-01 1962-04-11 Roche Products Ltd Novel tryptamine derivatives and a process for the manufacture thereof
GB966562A (en) * 1961-04-06 1964-08-12 Parke Davis & Co Amine compounds and means of producing the same
BE889931A (fr) * 1980-08-12 1982-02-11 Glaxo Group Ltd Derives indoliques, leur preparation et leurs applications en tant que medicaments
ZW19381A1 (en) * 1980-08-12 1983-03-09 Glaxo Group Ltd Heterocyclic compounds
US4803218A (en) * 1982-09-29 1989-02-07 Mcneilab, Inc. 3-aminoalkyl-1H-indole-5-urea and amide derivatives
GB8600397D0 (en) * 1986-01-08 1986-02-12 Glaxo Group Ltd Chemical compounds
GB8719167D0 (en) * 1987-08-13 1987-09-23 Glaxo Group Ltd Chemical compounds
GB8819024D0 (en) * 1988-08-10 1988-09-14 Glaxo Group Ltd Chemical compounds

Also Published As

Publication number Publication date
OA09874A (en) 1994-09-15
NO985607L (no) 1998-12-01
BG97632A (bg) 1994-03-31
MX9101606A (es) 1992-06-05
AU8950491A (en) 1992-05-20
JPH05507288A (ja) 1993-10-21
JP2677777B2 (ja) 1997-11-17
PT99218A (pt) 1992-09-30
NO985607D0 (no) 1998-12-01
DK0592438T5 (da) 1999-12-06
NO931378D0 (no) 1993-04-14
NZ270675A (en) 1997-07-27
JPH093063A (ja) 1997-01-07
NO305121B1 (no) 1999-04-06
NL300070I2 (nl) 2002-03-01
DE69127468D1 (de) 1997-10-02
HU225055B1 (en) 2006-05-29
CN1062529A (zh) 1992-07-08
LU90902I2 (fr) 2002-06-26
MY111683A (en) 2000-11-30
BR9106978A (pt) 1993-09-28
CA2091562C (en) 2001-03-27
FI931667A7 (fi) 1993-04-14
AU651637B2 (en) 1994-07-28
IL99701A0 (en) 1992-08-18
DE10299004I2 (de) 2006-03-16
NO2001019I1 (no) 2001-12-03
IE913555A1 (en) 1992-04-22
DE10299004I1 (de) 2002-05-08
FI105812B (fi) 2000-10-13
WO1992006973A1 (en) 1992-04-30
BR1100080A (pt) 2000-06-06
PT99218B (pt) 1999-04-30
SG54270A1 (en) 1998-11-16
PL169987B1 (en) 1996-09-30
RU2095360C1 (ru) 1997-11-10
NO931378L (no) 1993-04-14
ZA918156B (en) 1993-04-14
IL115117A (en) 1996-11-14
JP2575272B2 (ja) 1997-01-22
ATE157361T1 (de) 1997-09-15
CA2091562A1 (en) 1992-04-16
KR0179053B1 (ko) 1999-03-20
BG61975B1 (bg) 1998-11-30
HU9301098D0 (en) 1993-07-28
FI931667A0 (fi) 1993-04-14
GR3025087T3 (en) 1998-01-30
RO111767B1 (ro) 1997-01-30
IL99701A (en) 1996-10-31
EP0592438A1 (en) 1994-04-20
HUT64326A (en) 1993-12-28
YU165391A (sh) 1994-01-20
DK0592438T3 (da) 1997-09-29
DE9190141U1 (de) 1993-07-15
EP0592438B1 (en) 1997-08-27
YU48088B (sh) 1997-01-08
NZ240217A (en) 1995-05-26
PL168919B1 (pl) 1996-05-31
IL115117A0 (en) 1995-12-08
CN1039322C (zh) 1998-07-29
EG20224A (en) 1997-12-31
PL170330B1 (pl) 1996-11-29
NL300070I1 (nl) 2002-02-01
DE69127468T2 (de) 1998-01-02

Similar Documents

Publication Publication Date Title
BR9106978A (pt) Derivados de indol
ES2100907T3 (es) Bencimidazoles, medicamentos que contienen estos compuestos y proced imiento para su preparacion.
ES2166379T3 (es) 2-aminotetralinas sustituidas.
DE60107435D1 (de) 2-adamantylethylamine und deren verwendung bei der behandlung von abnormalitäten in der glutamat transmission
DE69005164D1 (de) Acryloylsubstituierte Pyrrol-Derivate.
ES2097496T3 (es) Derivados acilaminoindol como agonistas de 5-ht1.
AR007997A1 (es) Un derivado de distamicina sustituida con acriloilo, sus utilizaciones, un procedimiento para producirlo y una composicion farmaceutica que lo comprende.
ES2162404T3 (es) Nuevos derivados del indol y del indazol, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
ES2147316T3 (es) 1-cicloalqueniltetrazolinonas.
ATE203533T1 (de) INDOLDERIVATE ALS PRODRUGS VON ß5-HT1-LIKEß REZEPTOR AGONISTEN
PT90815A (pt) Processo de preparacao de derivados da fenotiazina
ES2053544T3 (es) Un procedimiento para la preparacion de nuevos derivados de indol tetraciclicos.
ES2031921T3 (es) Derivados 5-aminoetilados de la oxazolidinona-2, su procedimiento de fabricacion y su aplicacion terapeutica.
FR2589470B1 (fr) Nouveaux derives de l'imino-3 pyridazine, procede d'obtention et compositions pharmaceutiques
ES2063963T3 (es) Nuevas ariloxi-alquilaminas, su preparacion y medicamentos que las contienen.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 592438

Country of ref document: ES

SPCF Request for supplementary protection certificate filed

Free format text: ELETRIPTAN (RELPAX, RELERT)

Spc suppl protection certif: C200100041

Filing date: 20011113

SPCG Supplementary protection certificate granted

Free format text: ELETRIPTAN (RELPAX, RELERT).

Spc suppl protection certif: C200100041

Filing date: 20011113

Expiry date: 20160212

Effective date: 20040614